Replies to post #17546 on Avid Bioservices Inc (CDMO)

[keep_trying]

Senrex, Fair enough. The challenge is, how do investors get more transparency as to company business plan progress when prematurely revealing events can impact prospects for success?

As far as sending "a shot across the bow", my view is that long shareholders received a couple big ones with the events over the last three months because we are in the same boat as PPHM management. Some pretty big "shots" have come whistling by and there are those who are making calls that it is time to abandon ship, LOL! Allusions about those events having been caused by management methinks are more of an attempt to confuse investors enough to avoid clear recognition as to where the shots came from. More transparency from PPHM management would be nice in its own rite, but I observe that it is more transparency in the marketplace that is needed to reveal the hands that are pulling the triggers. Market disclosure rules still contain too much information down time in which parties can make investment decisions that are not revealed to investors in what is supposed to be an open, informed market place. By what justification should investors have to wait another six weeks to find out what happened to institutional holdings due to events of three months ago?

Working with your boat analogy, investors riding in the back of the boat that think they are accomplishing progress by taking shots at the guys in the helm at the same time that shots are being fired from other locales with apparent intent to sink or slow the boat need to show that they have a better plan for steering the boat that can be put into place before they run the ship aground. That said, I don't see TYP's proposals if implemented making for any meaningful change in the direction of boat Peregrine. The boat has already taken on the downside of the events in May through July and is still afloat, albeit riding lower in the water with a lower pps. Those seeking change may want to consider whether they would rather see management working to keep the ship on course towards business plan trial progress, repel boarders or dodge shots from the passenger section, LOL! I think PPHM management is already well aware that investors are restless.

Best wishes and IMO.
KT

[mojojojo]

"Why doesn't management attempt to license any PPHM technology outside of Bavi?"

http://www.peregrineinc.com/content.php?mi=Njg=

Platform Technology Partnering Opportunities

The overall goal of our licensing strategy is to develop a number of strategic relationships for the development of our platform technologies. There are numerous opportunities for exclusive and non exclusive licenses (access to our conceptual patents without exclusivity) of our Tumor Necrosis Therapy (TNT), Vascular Targeting Agents (VTA) , Vasopermeation Enhancement (VEA) and anti-angiogenesis platform technologies. Given our extensive technology portfolio, we intend to pursue structures such as out-licensing specific uses of our technologies, out-licensing exclusive uses of our technologies and joint collaboration development agreements. Our goal is to ensure that all of our technology platforms are under active development through the use of licensing and/or joint collaborations.

Because of the breadth of our patents, the licensing opportunities for our various technologies are numerous. The development of commercializable drug entities can, in many cases, require the combination of several different technologies, thus requiring access to several different patents for the final drug compound. For an overview of our patent portfolio please click here.

Clinical Program Partnering Opportunity

Peregrine is seeking corporate partnerships for joint development and marketing of Cotara®.

Please contact David King , Vice President, Business Development to discuss business development opportunities at Peregrine Pharmaceuticals, Inc. Telephone [phone].